Soligenix, Inc

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and commercializing HyBryteTM (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for...

Biotechnology,oncology,rare disease,rare cancers,oral mucositis,cutaneous t-cell lymphoma,ricin toxin vaccine,pediatric crohn’s disease,head and neck cancer,antibiotic resistant infectious disease,photodynamic therapy,heat stable vaccines,melioidosis,hypericin,ebola,innate defense regulator,infectious disease,acute radiation enteritis,ricin exposure,acute radiation syndrome,orphan diseases,and bioterrorism

Soligenix, inc operates in the Biotechnology industry.

Soligenix, inc's revenue is 11m - 100m

Soligenix, inc has 11 - 50 employees.